Alzheimer's disease: Is a vaccine possible?

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 6, 2014, Pages 438-444

  Alves, R P S ^a   Yang, M J ^b   Batista, M T ^a   Ferreira, L C S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Active immunization; Alzheimer's disease; Vaccine; amyloid

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; DNA VACCINE; EPITOPE; FC RECEPTOR; TAU PROTEIN; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; B LYMPHOCYTE; CALCIUM HOMEOSTASIS; COMPLEMENT ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; BRAIN; CLASSIFICATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; TRENDS; VACCINATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; VACCINATION;

EID: 84901661695     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143434     Document Type: Article

References (47)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 1995; 8: 429-431, doi: 10.1002/ca.980080612.
2. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-278, doi: 10.1016/0197-4580(95)00021-6.
3. Miniño AM, Xu J, Kochanek KD. Deaths: preliminary data for 2008. NVSR (National Vital Statistics Reports) Publication PHS 2011-1120. Washington: Centers for Disease Control and Prevention, National Center for Health Statistics. U.S. Government Printing Office; 2010.
4. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-1122, doi: 10.1001/archneur.60.8.1119.
5. Alzheimer's Disease International. World Alzheimer Report 2010. London: Alzheimer's Disease International; 2010.
6. United Nations PD. World population ageing: 1950-2050. New York: Department of Economic and Social Affairs; 2002.
7. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890, doi: 10.1016/S0006-291X(84)80190-4.
8. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985; 82: 4245-4249, doi: 10.1073/pnas.82. 12.4245.
9. Kurz A, Perneczky R. Amyloid clearance as a treatment target against Alzheimer's disease. J Alzheimers Dis 2011; 24 (Suppl 2): 61-73.
10. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 2002; 99: 6364-6369, doi: 10.1073/ pnas.092136199.
11. Pritchard SM, Dolan PJ, Vitkus A, Johnson GV. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med 2011; 15: 1621-1635, doi: 10.1111/j.1582-4934.2011.01273.x.
12. Giacobini E. Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease. Keio J Med 1987; 36: 381-391, doi: 10.2302/ kjm.36.381.
13. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989; 10: 593-602, doi: 10.1016/0197-4580(89)90143-7.
14. Dröes RM, Van Mierlo LD, Van der Roest HG, Meiland FJM. Focus and effectiveness of psychosocial interventions for people with dementia in institutional care settings from the perspective of coping with the disease. Non Pharm Ther Dement 2010; 1: 139-161.
15. Moreth J, Mavoungou C, Schindowski K. Passive antiamyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing 2013; 10: 18, doi: 10.1186/1742-4933-10-18.
16. Khorassani F, Hilas O. Bapineuzumab, an Investigational Agent For Alzheimer's Disease. P T 2013; 38: 89-91, PMC3628177.
17. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177, doi: 10.1038/22124.
18. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997; 94: 4109-4112, doi: 10.1073/pnas.94.8.4109.
19. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004; 15: 11-20, doi: 10.1016/ j.nbd.2003.09.015.
20. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in amouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-8855, doi: 10.1073/pnas.151261398.
21. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, et al. Generation of antibodies specific for betaamyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8: 1270-1275, doi: 10.1038/nm783.
22. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006; 6: 404-416, doi: 10.1038/nri1843.
23. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS One 2008; 3: e2124, doi: 10.1371/journal.pone.0002124.
24. Evans CF, Davtyan H, Petrushina I, Hovakimyan A, Davtyan A, Hannaman D, et al. Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques. Alzheimers Dement 2013; pii: S1552-5260(13)00656-0.
25. Guo W, Sha S, Xing X, Jiang T, Cao Y. Reduction of cerebral Abeta burden and improvement in cognitive function in Tg-APPswe/PSEN1dE9 mice following vaccination with a multivalent Abeta3-10 DNA vaccine. Neurosci Lett 2013; 549: 109-115, doi: 10.1016/j.neulet.2013.06.018.
26. Yu YZ, Wang S, Bai JY, Zhao M, Chen A, Wang WB, et al. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant. Clin Immunol 2013; 149: 11-24, doi: 10.1016/ j.clim.2013.05.016.
27. Ghochikyan A, Davtyan H, Petrushina I, Hovakimyan A, Movsesyan N, Davtyan A, et al. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother 2013; 9: 1002-1010, doi: 10.4161/hv.23875.
28. Matsumoto Y, Niimi N, Kohyama K. Development of a new DNA vaccine for Alzheimer disease targeting a wide range of abeta species and amyloidogenic peptides. PLoS One 2013; 8: e75203, doi: 10.1371/journal.pone.0075203.
29. Davtyan H, Ghochikyan A, Hovakimyan A, Petrushina I, Yu J, Flyer D, et al. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNAand recombinant protein-based Alzheimer's disease vaccines. J Neuroimmunol 2014; 268: 50-57, doi: 10.1016/ j.jneuroim.2014.01.002.
30. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/ oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci 2007; 27: 12721-12731, doi: 10.1523/JNEUROSCI.3201-07.2007.
31. Li Y, Ma Y, Zong LX, Xing XN, Guo R, Jiang TZ, et al. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Abeta3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice. J Neuroimmunol 2012; 249: 16-26, doi: 10.1016/j.jneuroim.2012.04.014.
32. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011; 31: 9323-9331, doi: 10.1523/JNEUROSCI. 0293-11.2011.
33. Bach P, Tschape JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, et al. Vaccination with Abeta-displaying viruslike particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenicmice. J Immunol 2009; 182: 7613-7624, doi: 10.4049/jimmunol.0803366.
34. Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 2013; 33: 4923-4934, doi: 10.1523/JNEUROSCI. 4672-12.2013.
35. Zou J, Yao Z, Zhang G, Wang H, Xu J, Yew DT, et al. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abetaspecific T cell response. J Neurol Sci 2008; 272: 87-98, doi: 10.1016/j.jns.2008.05.003.
36. Kim HD, Tahara K, Maxwell JA, Lalonde R, Fukuiwa T, Fujihashi K, et al. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med 2007; 9: 88-98, doi: 10.1002/jgm.993.
37. Lambracht-Washington D, Qu BX, Fu M, Anderson LDJr, Eagar TN, Stuve O, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Abeta42 DNA vaccine for Alzheimer disease. J Neuroimmunol 2013; 254: 63-68, doi: 10.1016/j.jneuroim.2012.09.008.
38. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 2013; 248: 451-456, doi: 10.1016/j.expneurol.2013.07.006.
39. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101, doi: 10.1212/01.WNL.0000148 604.77591.67.
40. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20, doi: 10.1111/j.1750-3639.200 4.tb00493.x.
41. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452, doi: 10.1038/nm840.
42. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54, doi: 10.1212/01.WNL.0000073623.84147.A8.
43. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562, doi: 10.1212/01.WNL.0000159740.16984.3C.
44. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15: 505-514, doi: 10.1093/intimm/dxg049.
45. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to betaamyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100: 2023-2028, doi: 10.1073/pnas.0436286100.
46. Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, et al. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 2007; 282: 22376-22386, doi: 10.1074/jbc.M700088200.
47. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, doubleblind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11: 597-604, doi: 10.1016/S1474-4422(12) 70140-0.